Krystexxa, a medication used to treat chronic refractory gout, has an annual cost that can exceed $70,000. The price per vial can range from approximately $4,000 to over $5,000, with patients typically requiring multiple doses per year [1][2]. This cost contributes to Krystexxa being one of the more expensive gout treatments available [3].
How is Krystexxa administered?
Krystexxa is administered as an intravenous (IV) infusion. Dosing typically involves an initial infusion, followed by a second infusion four weeks later, and then subsequent infusions every four weeks thereafter. The specific frequency and duration of treatment are determined by a healthcare provider based on the individual patient's response [4].
What is the difference between Krystexxa and other gout medications?
Krystexxa is a biologic medication that works by breaking down uric acid in the body. It is used for patients with chronic refractory gout who have not responded to other treatments. Unlike other gout medications, such as allopurinol or febuxostat, which reduce uric acid production, or probenecid, which increases uric acid excretion, Krystexxa targets established uric acid crystals, dissolving them over time [4][5]. Other oral medications for gout are typically much less expensive than Krystexxa [3].
When does Krystexxa patent expiry?
The patent landscape for Krystexxa (pegloticase) is complex. While primary patents for the drug may be expiring or have expired, additional patents related to manufacturing processes or specific formulations can extend market exclusivity. Information on specific patent expiry dates can be found on specialized databases like DrugPatentWatch.com [6].
Are there patient assistance programs for Krystexxa?
Yes, patient assistance programs are often available to help eligible individuals manage the cost of Krystexxa. These programs, sometimes offered by the manufacturer or independent foundations, may provide financial assistance or co-pay support for those who meet specific income and insurance criteria [7][8].
What are the potential side effects of Krystexxa?
Common side effects associated with Krystexxa include infusion reactions, such as flushing, itching, hives, and difficulty breathing. Other potential side effects can involve upper respiratory infections, nausea, bruising, constipation, and gastrointestinal issues [4]. Due to the risk of infusion reactions, patients are often monitored during and after administration.
How effective is Krystexxa in treating chronic refractory gout?
Krystexxa has demonstrated effectiveness in reducing serum uric acid levels and decreasing the frequency of gout flares in patients with chronic refractory gout. Clinical trials have shown significant reductions in uric acid levels and a substantial decrease in the number of gout attacks for patients treated with Krystexxa compared to placebo [4][9].
Who manufactures Krystexxa?
Krystexxa is manufactured by Horizon Therapeutics [10].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/krystexxa
[2] https://www.goodrx.com/krystexxa
[3] https://www.yalemedicine.org/conditions/gout
[4] https://www.hcp.arzerra.com/hcp/gout/krystexxa/mechanism-of-action
[5] https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-20373111
[6] https://www.drugpatentwatch.com/drug/krystexxa
[7] https://www.horizontherapeutics.com/patients/patient-support
[8] https://www.patientadvocate.org/find-a-program/?keyword=Krystexxa
[9] https://pubmed.ncbi.nlm.nih.gov/27069027/
[10] https://www.drugs.com/manufacturer/horizon-therapeutics-688.html